Skip to content
AnalystLens

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2025

Filing Date
Filed October 23, 2025
Period End
September 30, 2025
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jul ’24Jul ’24

Summary

Summary of the 10-Q filed October 23, 2025. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported its third-quarter 2025 results in this Form 10-Q for the period ended September 30, 2025.

Revenue, net was $659.9 milliona for the three months ended September 30, 2025, up from $533.3 million a year earlier, and $1.82 billion for the nine months, up from $1.57 billion. Net income was $111.1 million for the quarter (diluted EPS $3.86) and $316.0 million for the nine months (diluted EPS $10.64). Income from operations rose to $141.8 million for the quarter and $381.7 million for the nine months.

Net new business awards were $789.6 millionb for the quarter and $1.91 billion for the nine months, and backlog stood at $3,000.6 million as of September 30, 2025. The balance sheet shows a significant shift in capital allocation. Cash and cash equivalents declined to $285.4 million from $669.4 million at December 31, 2024, primarily due to share repurchases.

The company repurchased 2,961,924 shares for $912.9 millionc during the nine months, leaving $821.7 million of remaining authorization. Total shareholders' equity fell to $293.6 million from $825.5 million, and the accumulated deficit was $(596.2) million compared with retained earnings of $8.2 million at year-end 2024. Net cash from operating activities was $520.6 million for the nine months, and the company reported no indebtedness under its $10.0 million credit facility.

The company stated that its disclosure controls and procedures were effective, and it reported no material changes to its market risk disclosures or risk factors relative to its 2024 Form 10-K. Advanced billings increased to $834.3 milliond, and the company disclosed approximately $3.5 billion of performance obligations remaining on active projects.

Key Highlights

  1. Total revenue of $659.9 million for Q3 2025, up from $533.3 million in Q3 2024, and $1,821.8 million for the nine months, up from $1,572.5 million.
  2. Income from operations of $141.8 million for Q3 2025 versus $112.3 million in Q3 2024; net income of $111.1 million, with diluted EPS of $3.86 versus $3.01.
  3. Backlog of $3,000.6 million at September 30, 2025, compared with $2,927.4 million a year earlier; net new business awards were $789.6 million for the quarter and $1,910.2 million for the nine months.
  4. Share repurchases of $912.9 million for 2,961,924 shares during the nine months ended September 30, 2025, versus no repurchases in the prior-year period; $821.7 million remains under the program.
  5. Cash and cash equivalents fell to $285.4 million from $669.4 million at December 31, 2024, and shareholders' equity fell to $293.6 million from $825.5 million.
  6. Operating cash flow was $520.6 million for the nine months, and the company had no indebtedness under its $10.0 million Credit Facility as of September 30, 2025.
  7. Effective tax rate rose to 22.2% for the quarter from 18.8% a year earlier, mainly due to lower estimated FDII tax benefits.

Financial Statements

Q3 FY2025 against Q3 FY2024

Line itemQ3 FY2025Q3 FY2024Change
Revenue$659.90M$533.32M+23.7%
SG&A Expenses$48.08M$49.22M−2.3%
Operating Expenses$518.10M$421.04M+23.1%
Operating Income$141.81M$112.27M+26.3%
Net Income$111.14M$96.43M+15.3%
EPS (Basic)$3.95$3.11+27.0%
EPS (Diluted)$3.86$3.01+28.2%
Shares Outstanding (Basic)28.14M31.05M−9.4%
Shares Outstanding (Diluted)28.82M32.09M−10.2%

Frequently Asked Questions

  1. How did Medpace perform in the third quarter of 2025?

    Revenue, net rose to $659.9 million from $533.3 million, and income from operations increased to $141.8 million from $112.3 million. Net income was $111.1 million, compared with $96.4 million in the prior-year quarter.

  2. Why did cash and equity decline so sharply in 2025?

    The filing attributes the decline in cash and cash equivalents primarily to share repurchases. The company repurchased $912.9 million of shares during the nine months ended September 30, 2025, which also reduced total shareholders' equity to $293.6 million and produced an accumulated deficit of $(596.2) million.

  3. What does the backlog and new business activity indicate?

    Backlog was $3,000.6 million at September 30, 2025, up from $2,927.4 million a year earlier. Net new business awards were $789.6 million for the quarter and $1,910.2 million for the nine months, compared with $533.7 million and $1,700.3 million in the prior-year periods. The filing notes that backlog and award metrics may not reliably predict future revenue. Approximately $1,830.0 million to $1,850.0 million of backlog is expected to convert to revenue over the next twelve months.

  4. Did anything change in the company's tax position or liquidity?

    The effective tax rate was 22.2% for the quarter, compared with 18.8% a year earlier, primarily due to a decrease in estimated FDII tax benefits. The company had no borrowings under its $10.0 million Credit Facility, and its full $10.0 million remained available as of September 30, 2025.